-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $8

Benzinga·11/10/2026 15:55:12
Truist Securities analyst Gregory Renza maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $11 to $8.